Bright-field in situ hybridization detects gene alterations and viral infections useful for personalized management of cancer patients

Chiara C. Volpi, Ambra V. Gualeni, Filippo Pietrantonio, Emanuela Vaccher, Antonino Carbone, Annunziata Gloghini

Research output: Contribution to journalReview article

Abstract

Introduction: Bright-field in situ hybridization (ISH) methods detect gene alterations that may improve diagnostic precision and personalized management of cancer patients. Areas covered: This review focuses on some bright-field ISH techniques for detection of gene amplification or viral infection that have already been introduced in tumor pathology, research and diagnostic practice. Other emerging ISH methods, for the detection of translocation, mRNA and microRNA have recently been developed and need both an optimization and analytical validation. The review also deals with their clinical applications and implications on the management of cancer patients. Expert commentary: The technology of bright-field ISH applications has advanced significantly in the last decade. For example, an automated dual-color assay was developed as a clinical test for selecting cancer patients that are candidates for personalized therapy. Recently an emerging bright-field gene-protein assay has been developed. This method simultaneously detects the protein, gene and centromeric targets in the context of tissue morphology, and might be useful in assessing the HER2 status particularly in equivocal cases or samples with heterogeneous tumors. The application of bright-field ISH methods has become the gold standard for the detection of tumor-associated viral infection as diagnostic or prognostic factors.

Original languageEnglish
Pages (from-to)259-277
Number of pages19
JournalExpert Review of Molecular Diagnostics
Volume18
Issue number3
DOIs
Publication statusPublished - Mar 4 2018

Fingerprint

Virus Diseases
In Situ Hybridization
Genes
Neoplasms
Gene Amplification
MicroRNAs
Proteins
Color
Pathology
Technology
Messenger RNA
Research

Keywords

  • Bright-field in situ hybridization
  • diagnostic precision
  • DNA detection
  • gene amplification
  • gene rearrangements
  • personalized treatment
  • RNA detection
  • cancer patient
  • neoplasms

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Bright-field in situ hybridization detects gene alterations and viral infections useful for personalized management of cancer patients. / Volpi, Chiara C.; Gualeni, Ambra V.; Pietrantonio, Filippo; Vaccher, Emanuela; Carbone, Antonino; Gloghini, Annunziata.

In: Expert Review of Molecular Diagnostics, Vol. 18, No. 3, 04.03.2018, p. 259-277.

Research output: Contribution to journalReview article

@article{7bdde4945fd94f8aabf6a6bd0a87d639,
title = "Bright-field in situ hybridization detects gene alterations and viral infections useful for personalized management of cancer patients",
abstract = "Introduction: Bright-field in situ hybridization (ISH) methods detect gene alterations that may improve diagnostic precision and personalized management of cancer patients. Areas covered: This review focuses on some bright-field ISH techniques for detection of gene amplification or viral infection that have already been introduced in tumor pathology, research and diagnostic practice. Other emerging ISH methods, for the detection of translocation, mRNA and microRNA have recently been developed and need both an optimization and analytical validation. The review also deals with their clinical applications and implications on the management of cancer patients. Expert commentary: The technology of bright-field ISH applications has advanced significantly in the last decade. For example, an automated dual-color assay was developed as a clinical test for selecting cancer patients that are candidates for personalized therapy. Recently an emerging bright-field gene-protein assay has been developed. This method simultaneously detects the protein, gene and centromeric targets in the context of tissue morphology, and might be useful in assessing the HER2 status particularly in equivocal cases or samples with heterogeneous tumors. The application of bright-field ISH methods has become the gold standard for the detection of tumor-associated viral infection as diagnostic or prognostic factors.",
keywords = "Bright-field in situ hybridization, diagnostic precision, DNA detection, gene amplification, gene rearrangements, personalized treatment, RNA detection, cancer patient, neoplasms",
author = "Volpi, {Chiara C.} and Gualeni, {Ambra V.} and Filippo Pietrantonio and Emanuela Vaccher and Antonino Carbone and Annunziata Gloghini",
year = "2018",
month = "3",
day = "4",
doi = "10.1080/14737159.2018.1440210",
language = "English",
volume = "18",
pages = "259--277",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Bright-field in situ hybridization detects gene alterations and viral infections useful for personalized management of cancer patients

AU - Volpi, Chiara C.

AU - Gualeni, Ambra V.

AU - Pietrantonio, Filippo

AU - Vaccher, Emanuela

AU - Carbone, Antonino

AU - Gloghini, Annunziata

PY - 2018/3/4

Y1 - 2018/3/4

N2 - Introduction: Bright-field in situ hybridization (ISH) methods detect gene alterations that may improve diagnostic precision and personalized management of cancer patients. Areas covered: This review focuses on some bright-field ISH techniques for detection of gene amplification or viral infection that have already been introduced in tumor pathology, research and diagnostic practice. Other emerging ISH methods, for the detection of translocation, mRNA and microRNA have recently been developed and need both an optimization and analytical validation. The review also deals with their clinical applications and implications on the management of cancer patients. Expert commentary: The technology of bright-field ISH applications has advanced significantly in the last decade. For example, an automated dual-color assay was developed as a clinical test for selecting cancer patients that are candidates for personalized therapy. Recently an emerging bright-field gene-protein assay has been developed. This method simultaneously detects the protein, gene and centromeric targets in the context of tissue morphology, and might be useful in assessing the HER2 status particularly in equivocal cases or samples with heterogeneous tumors. The application of bright-field ISH methods has become the gold standard for the detection of tumor-associated viral infection as diagnostic or prognostic factors.

AB - Introduction: Bright-field in situ hybridization (ISH) methods detect gene alterations that may improve diagnostic precision and personalized management of cancer patients. Areas covered: This review focuses on some bright-field ISH techniques for detection of gene amplification or viral infection that have already been introduced in tumor pathology, research and diagnostic practice. Other emerging ISH methods, for the detection of translocation, mRNA and microRNA have recently been developed and need both an optimization and analytical validation. The review also deals with their clinical applications and implications on the management of cancer patients. Expert commentary: The technology of bright-field ISH applications has advanced significantly in the last decade. For example, an automated dual-color assay was developed as a clinical test for selecting cancer patients that are candidates for personalized therapy. Recently an emerging bright-field gene-protein assay has been developed. This method simultaneously detects the protein, gene and centromeric targets in the context of tissue morphology, and might be useful in assessing the HER2 status particularly in equivocal cases or samples with heterogeneous tumors. The application of bright-field ISH methods has become the gold standard for the detection of tumor-associated viral infection as diagnostic or prognostic factors.

KW - Bright-field in situ hybridization

KW - diagnostic precision

KW - DNA detection

KW - gene amplification

KW - gene rearrangements

KW - personalized treatment

KW - RNA detection

KW - cancer patient

KW - neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85044021845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044021845&partnerID=8YFLogxK

U2 - 10.1080/14737159.2018.1440210

DO - 10.1080/14737159.2018.1440210

M3 - Review article

VL - 18

SP - 259

EP - 277

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 3

ER -